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Abstract
RA is a chronic, debilitating disease in which articular inflammation and joint destruction are accompanied
by systemic manifestations including anaemia, fatigue and osteoporosis. IL-6 is expressed abundantly in
the SF of RA patients and is thought to mediate many of the local and systemic effects of this disease.
Unlike a number of other cytokines, IL-6 can activate cells through both membrane-bound (IL-6R) and
soluble receptors (sIL-6R), thus widening the number of cell types responsive to this cytokine. Indeed,
trans-signalling, where IL-6 binds to the sIL-6R, homodimerizes with glycoprotein 130 subunits and
induces signal transduction, has been found to play a key role in acute and chronic inflammation.
Elevated levels of IL-6 and sIL-6R in the SF of RA patients can increase the risk of joint destruction
and, at the joint level, IL-6/sIL-6R can stimulate pannus development through increased VEGF expression
and increase bone resorption as a result of osteoclastogenesis. Systemic effects of IL-6, albeit through
conventional or trans-signalling, include regulation of acute-phase protein synthesis, as well as hepcidin
production and stimulation of the hypothalamo-pituitary-adrenal axis, the latter two actions potentially
leading to anaemia and fatigue, respectively. This review aims to provide an insight into the biological
effects of IL-6 in RA, examining how IL-6 can induce the articular and systemic effects of this disease.
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Introduction
RA is a chronic inflammatory disease characterized by
articular inflammation leading to joint destruction. RA
pathogenesis involves complex humoral and cellular
reactions including IC formation, vascular reactions and
infiltration of lymphocytes and monocytes into the syno-
vium. These infiltrating cells and synoviocytes release pro-
inflammatory mediators, including IL-6, which perpetuate
inflammation and destruction through effects on other cell
types in the synovium and peri-articular structures (Fig. 1).
It is thought that RA is linked initially to immunity against
an unknown antigen and later to self-maintained inflam-
matory processes [1]. The presence of autoantibodies
such as anti-cyclic citrullinated peptide [2] and increased
CRP levels [3] many years before the appearance of
clinical symptoms suggests a role for dysregulation of
the immune response in the pathogenesis of this disease.
Since IL-6 is important in B-cell maturation and therefore
production of autoantibodies, as well as the direct
stimulation of CRP from hepatocytes, it may play a
significant role in RA pathogenesis [4]. In animal models
of autoimmune diseases, IL-6 plays a critical role in the
generation of Th17 pro-inflammatory lymphocytes, thus
increasing this possibility further [5]. In patients with
established RA, many of the articular and systematic
manifestations could be explained by the effect of IL-6.
The combination of articular and systemic effects of
IL-6 makes inhibition of the IL-6R a logical target for
treatment of patients with RA. This review will provide
a perspective on how IL-6 induces the articular and
systemic symptoms of RA.
IL-6 biology
Multi-target cytokine
IL-6 is a 26-kDa glycopeptide whose gene is found
on chromosome 7. It has previously been known as
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Whepatocyte-stimulating factor, cytotoxic T-cell differentia-
tion factor, B-cell differentiation factor, B-cell stimulatory
factor 2, hybridoma/plasmacytoma growth factor,
monocyte granulocyte inducer type 2 and thrombopoietin.
The many names reflect the pleiotropism of IL-6. The IL-6-
like family of cytokines has more than 10 members,
including IL-11 and leukaemia inhibitory factor [4, 6].
Receptor binding
IL-6 signals primarily through a protein complex including
the membrane-bound, non-signalling a-receptor subunit
(IL-6R) and two signal-transducing gp130 subunits
(Fig. 2A) [4]. While gp130 is expressed ubiquitously,
IL-6R is predominantly expressed on hepatocytes,
neutrophils, monocytes/macrophages and some lympho-
cytes [4]. However, IL-6 can also signal via a soluble
receptor (sIL-6R) that lacks transmembrane and cytoplas-
mic components. Activated sIL-6R binds to membrane-
bound gp130 subunits in a process known as trans-
signalling (Fig. 2B) [4, 7]. sIL-6R is generated either by
limited proteolysis of the membrane-bound IL-6R or
by alternative mRNA splicing. sIL-6R is transported in
bodily fluids and increases the variety of cells able to
FIG.1Inflammatory pathways activated by IL-6. At joint level, IL-6 induces pannus formation, osteoclast activation and
mediates chronic synovitis.
FIG.2IL-6 signalling mechanism. IL-6-mediated signal transduction through classical (A) and trans-signalling
(B) pathways. In IL-6 trans-signalling, sIL-6R is generated either by limited proteolysis of the membrane-bound IL-6R
or by alternative mRNA splicing. In both classical and trans-signalling, responses are elicited through engagement with
membrane-bound gp130.
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synoviocytes express gp130 but not IL-6R, and can there-
fore only respond to IL-6 in the presence of sIL-6R.
Indeed, IL-6 and sIL-6R induce tubule formation in fibro-
blast-like synovial cells from RA patients, an effect not
observed with IL-6 alone or indeed TNF-a [8].
The key role of trans-signalling in RA has been demon-
strated recently in a murine experimental arthritis model in
which blocking IL-6 trans-signalling using a variant soluble
gp130 molecule resulted in a marked clinical improvement
in systemic arthritis [9]. These findings support earlier data
showing restoration of experimental arthritis disease
activity in an IL-6 knock-out mouse model when adminis-
tered with an sIL-6R–IL-6 fusion protein [10].
Receptor activation
The increase in IL-6 and sIL-6R in SF increases the risk of
joint destruction in RA [11]. Once IL-6 binds its receptor
and gp130 homodimerization occurs, a signalling cascade
is triggered. The Janus kinases are activated, followed by
the recruitment of signal transducers and activators of
transcriptions (STATs). Phosphorylated STATs translocate
to the nucleus where they activate gene transcription
[12, 13]. IL-6 also activates the mitogen-activated protein
kinase cascade, which is upstream of various molecules
involved in cell survival and stress responses [14]. IL-6R
stimulation also recruits other signal transduction
molecules, including SH2 domain-containing tyrosine
phosphatase (SHP2) and suppressor of cytokine signal-
ling (SOCS). Both SHP2 and SOCS may subsequently
down-regulate IL-6 signalling [12].
The role of IL-6 in the adaptive immune
response
RA is characterized by an increase in IgM and IgG RFs
and antibodies to citrullinated peptides in both serum and
joints. B-cell depletion is of therapeutic benefit in RA and
demonstrates the impact of B-cell activity on synovial
inflammation and joint damage in this disease. IL-6 was
originally identified as a B-cell differentiation factor;
it plays an important role in the development of anti-
body-producing plasma B cells [15]. IL-6 induces B-cell
differentiation through its action on plasmablasts [16] and
more recently has been shown to induce B-cell antibody
production indirectly by promoting the B-cell helper
properties of CD4
þ T cells via the production of IL-21 [17].
In addition to B-cell development, IL-6 influences T-cell
development. When activated, naı ¨ve T cells develop into
either effector or regulatory T cells [18]. Effector T cells are
further subdivided into Th1, -2 and -17 cells, all of which
have pro-inflammatory properties. Animal studies have
shown that Th17 cells are important mediators in autoim-
mune diseases and the host defense against extracellular
pathogens. Th17 cells produce IL-17, -12 and -22.
In murine models of autoimmune diseases, differentiation
of Th17 is regulated by the cytokine milieu. In the
presence of TGF-b alone, naı ¨ve T cells differentiate into
regulatory T cells and development of Th17 cells is
suppressed. When IL-6 is present together with TGF-b,
naı ¨ve T cells develop into Th17 cells through activation
of STAT3 and induction of the transcription factor retinoic
acid-related orphan receptor (RORgammat). IL-23, which
also activates STAT3, is important in the maintenance of
Th17 cells. In humans, however, it appears this pathway,
and is driven by IL-6 in combination with IL-1b and -23
rather than TGF-b [5, 19, 20]. In addition, in vitro activated
monocytes as well as in vivo activated monocytes from
the rheumatoid joint drive Th17 induction from memory
T cells via the production or expression of inflammatory
mediators [21, 22].
Th17 cells are also involved in the host defense
response against bacteria and fungi, suggesting that
IL-6 may contribute indirectly to fighting infection through
Th17 cell development [5, 23]. For example, IL-6-induced
activation of STAT proteins is important in the recruitment
of neutrophils during Escherichia coli pneumonia infection
[24]. Differences between pro-inflammatory cytokines
have been observed in a number of infections. For exam-
ple, although TNF-a has been found to be involved in
the formation and maintenance of granulomas during
infection with Mycobacterium tuberculosis, there is little
evidence to suggest involvement of IL-6 in granuloma
preservation [25–28]. Overall, these findings demonstrate
that IL-6 has an important role in the development of the
adaptive immune response and may be involved in the
pathogenesis of RA.
The effects of IL-6 at joint level
The role of IL-6in the shift from acute to chronic
inflammation
Neutrophils are important mediators of inflammation and
joint destruction in RA due to their ability to secrete
proteolytic enzymes and reactive oxygen intermediates.
IL-6 acts directly on neutrophils through membrane-
bound IL-6R. When endothelial cells were co-cultured
with fibroblasts isolated from the synovium of RA patients,
IL-6 levels increased and neutrophils adhered [29]; anti-IL-
6 antibodies prevented this neutrophil adhesion. In vivo,
IL-6-negative transgenic mice show defective leucocyte
recruitment into the air pouch [30]. Similarly, in wild-type
mice, introduction of an anti-IL-6 antibody reduced
leucocyte infiltration to levels observed in the transgenic
mice. Other reported effects of IL-6 on neutrophils include
survival, activation of proliferation through inflammatory
cytokines, mobilization of marginated neutrophils into
the circulation and transit of neutrophils from the bone
marrow [31–35].
During acute inflammation in RA, monocytes, macro-
phages and endothelial cells release IL-6, accompanied
by an increase in neutrophils in SFs. As disease pro-
gresses, IL-6 is thought to influence the shift from acute
to chronic inflammation [36], marked by an increase in the
recruitment of monocytes.
The release of sIL-6R is thought to play a key role in
the regulation of acute and chronic inflammation. Indeed,
sIL-6R release from neutrophils as they reach the site of
www.rheumatology.oxfordjournals.org 17
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through activation of adjacent endothelial cells and sub-
sequent chemokine release [30, 37–39]. This may be an
important rate-limiting step for inflammation. In particular,
sIL-6R signalling increases the amounts of monocyte-
specific, but not neutrophil-specific chemo-attractants
secreted by endothelial cells [40]. Thus, activation of
endothelial cells through trans-signalling results in a
shift from neutrophil to monocyte infiltration.
The role of IL-6in extracellular matrix turnover
Extracellular matrix is the target of proteinases such as
MMPs and disintegrin-metalloproteinases with thrombos-
pondin motifs. Proteinases in RA are produced by
synovial lining cells, sublining fibroblasts and infiltrating
leucocytes and macrophages [41–48]. Several studies
have shown a correlation between articular cartilage
destruction and the expression of MMPs [49–51].
Cells lining the synovium in RA have been shown to
overproduce MMPs, with plasma levels of MMP-2 and
-9 higher in RA patients than controls [41, 44, 45, 47,
52]. Both IL-6 and sIL-6R increased collagenase-3
mRNA and protein levels in rat osteoblast cultures [53,
54]. However, this situation has not been demonstrated
in humans. Although some studies suggest that IL-6 does
not stimulate proteinase production or activity [55, 56],
correlations between IL-6 and CRP, as well as CRP and
proMMP-3, have been identified in patients with early RA
[57]. These findings suggest a link between proteinase
activity and IL-6 levels.
Tissue inhibitors of MMPs (TIMPs) are endogenous
inhibitors of MMPs. IL-6, in the presence of sIL-6R,
induced TIMP-1 mRNA and protein expression in cultured
human chondrocytes and synovial fibroblasts [58]. The
ability of culture supernatants from IL-6/sIL-6R-stimulated
cells to inhibit collagen digestion in IL-1-stimulated syno-
vial cells further supports IL-6-induced TIMP production
and the role of IL-6 in extracellular matrix turnover [58].
TheroleofIL-6inthedevelopmentofarticularsymptoms
ofRA
IL-6 is abundantly expressed in the synovium in RA [59].
Levels of IL-6 and sIL-6R in SF correlate significantly with
local joint measures of chronic synovitis and the severity
of joint destruction in patients with RA [60], as does sIL-6R
with leucocyte infiltration [61]. Moreover, the sIL-6R:IL-6
ratio is significantly higher in patients with Stage 1 and 2
disease, according to Mallya and Mace [62, 63] assess-
ment of disease activity, compared with patients with
Stage 4 disease.
IL-6 can also promote joint inflammation and damage
through its effect on VEGF levels in RA patients. VEGF is
a potent angiogenic factor that promotes the migration
and proliferation of endothelial cells, as well as inducing
vascular permeability and mediating inflammation [64, 65].
Significant increases in VEGF levels in RA patients
correlate with disease activity, suggesting that VEGF is
implicated in RA pathogenesis, particularly in pannus
formation [66]. IL-6, in the presence of sIL-6R, increased
VEGF levels in cultured synovial fibroblasts from RA
patients [67]. In these cell cultures, anti-IL-6R antibody
significantly reduced VEGF concentration.
Effects ofIL-6 onerosion
Joint damage in RA is characterized by erosions and joint
space narrowing indicating destruction of bone and
articular cartilage. In human and animal studies, osteo-
clasts have been identified as the key cell type-mediating
erosions in inflammatory arthritis [68]. IL-6 increases
osteoclast recruitment by acting on haematopoietic
stem cells from the granulocyte–macrophage lineage
[69–71].
A number of in vitro and in vivo studies have looked
at the effects of IL-6 and sIL-6R on osteoclastogenesis
and bone resorption. In an in vitro study, IL-6-induced
osteoclast differentiation is indirect and appears to be
mediated via interaction with osteoblasts through the
sIL-6R, resulting in PGE2 synthesis. PGE2 acts in an
autocrine manner to induce the RANK-ligand expression
and down-regulate osteoprogerin expression leading to
enhanced osteoclastogenesis [11, 72, 73]. In mouse
calvarial bone cultures, IL-6, in the presence of sIL-6R,
induced bone resorption, which was decreased by osteo-
clast inhibitors, suggesting that sIL-6R trans-signalling
influences osteoclastogenesis [72]. In vivo, a reduction in
the severity of antigen-induced arthritis was observed in
IL-6-deficient mice compared with wild-type mice [73].
In addition, the IL-6-deficient mice had markedly reduced
osteoclast recruitment to the sites of joint disease, as well
as lower IL-17 levels. In humans, however, the effect of
IL-6 on PGE2 production is not established. Moreover, it
has recently been suggested that, under normal con-
ditions, IL-6 suppresses bone resorption by specifically
inhibiting the RANK signalling pathway. In RA, IL-6 and
sIL-6R induced osteoclastogenesis in osteoclast-like
multinucleated cells obtained from RA patients, at the
concentrations found within the SF of RA patients.
This process was inhibited by anti-IL-6 [11].
IL-6 also exerts effects on the components of the
articular cartilage. Proteoglycans are the principal com-
ponent of articular cartilage and the depletion of these in
RA contributes to cartilage degradation. In cultures of
human articular chondrocytes from patients with RA
[74], either IL-6 or sIL-6R alone induced a small inhibitory
effect on proteoglycan synthesis. However, the combina-
tion of sIL-6R and IL-6 markedly increased the inhibition,
again suggesting a key role for IL-6 in causing joint
damage in RA.
The role of IL-6 in the development of
systemic symptoms of RA
Acute-phase response
The acute-phase response, one of the body’s first reac-
tions to injury, is characterized by a number of systemic
changes. These include the release of pro-inflammatory
cytokines and alterations in the level of acute-phase
proteins in the plasma [75, 76]. Acute-phase proteins are
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negative, depending on whether their concentrations
increase during inflammation (e.g. CRP and TIMPs) or
decrease (e.g. apolipoprotein A1 and transferrin). IL-6 is
a principal stimulator of acute-phase protein synthesis
through hepatocyte stimulation. In patients with RA,
serum IL-6 levels correlate with CRP levels [59]. As IL-6
is easily measured in biological fluids, it can be used as
a biomarker of inflammation and disease activity [59, 77]
(Fig. 3).
Anaemia ofchronic inflammation
Anaemia is the most common systemic manifestation of
RA. Defined as haemoglobin (Hb) levels <13g/dl in men
and <12g/dl in women, anaemia is present in more than
a third of RA patients and in a quarter of patients within
the first year of disease [78, 79]. Patients with RA and
anaemia have more severe physical disability compared
with non-anaemic patients (Hb>14g/dl) [78].
The peptide hepcidin is produced by hepatocytes and
regulates iron metabolism by preventing iron transport
and the release of iron from macrophages [80]. In vitro,
IL-6 stimulation of human hepatoma cells induced
hepcidin expression [81]. In wild-type mice, turpentine
stimulation of the inflammatory response resulted in
marked increase in liver hepcidin expression accom-
panied by a decrease in serum iron, whereas in IL-6
knock-out mice, hepcidin levels were below baseline
levels and iron levels increased slightly [81]. Moreover,
IL-6 infusion resulted in a rapid 7.5-fold increase in
hepcidin secretion in healthy volunteers [81]. Thus, the
IL-6–hepcidin axis has a vital role in the anaemia
of inflammation observed in many RA patients.
Systemic osteoporosis
Osteoporosis, a common systemic manifestation of RA,
is also linked with IL-6. Bone remodelling requires a
careful balance between the actions of bone-resorbing
osteoclasts and bone-forming osteoblasts. Dysregulation
of this process can lead to overall bone loss. Transgenic
mice over-expressing IL-6 have been shown to have
decreased osteoblast and increased osteoclast numbers
[82]. Accelerated bone resorption, reduced bone forma-
tion and defective ossification were also reported, sug-
gesting that IL-6 over-expression results in osteopaenia
due to osteoclast and osteoblast dysregulation.
Fatigue andhypothalamo-pituitary-adrenal (HPA) axis
Fatigue is a commonly reported problem in patients with
RA, with 41% experiencing clinically important levels of
fatigue [83–85]. For a number of years, IL-6 has been
known to influence fatigue and sleep, with healthy volun-
teers recording increased fatigue, inactivity and lack of
concentration following IL-6 administration vs placebo
[86]. These IL-6-induced effects were found to correspond
with HPA axis function. More recently, IL-6 production has
been correlated with reports of fatigue in patients with RA,
providing further evidence of the link between IL-6 and
fatigue [87].
IL-6, lipids and inflammation
Patients with RA are at increased risk of cardiovascular
disease. The atherogenic effects of systemic inflammation
manifest themselves at different levels, including endothe-
lial dysfunction and dyslipidaemia [88–90]. Elevated CRP
levels are associated with increased risk of cardiovascular
disease [91], hospitalization and hospital mortality,
although more research is required to determine the
direct role of CRP [92, 93].
Inflammation through the effects of IL-6 reduces circu-
lating lipid levels. When IL-6 was administrated to normal
healthy volunteers [94], within 24h of IL-6 administration,
total cholesterol, apolipoprotein B and triglyceride were
reduced. The exact mechanism by which IL-6 induces
these changes remains unknown. However, IL-6 has
been shown to affect lipid metabolism by stimulating
hepatic fatty acid synthesis and adipose tissue lipolysis.
In addition, IL-6 increases cholesterol synthesis while
decreasing cholesterol secretion [95, 96].
Independent of the effect on lipids, IL-6 and CRP have
been associated with increased cardiovascular risk in
apparently normal healthy males [97] and females [98].
Furthermore, IL-6 is associated with increased mortality
in patients with acute coronary syndromes [99]. Serum
IL-6 levels were significantly higher in patients with a
complicated in-hospital course, compared with those
demonstrating an uncomplicated course. In addition,
decreases in IL-6 within 48h were associated with
uncomplicated outcomes, whereas increases in IL-6
were associated with complications. These data implicate
IL-6 in the development of coronary artery disease.
IL-6R inhibition in the treatment of RA
Recent advances in understanding of RA pathogenesis
have identified a number of potential targets for
FIG.3The systemic effects of IL-6. Systemically, IL-6
actions include stimulation of acute-phase proteins and
hepatocyte proliferation in the liver, induction of anaemia
and effects on lipids and lipid metabolism, impairment
of HPA axis and osteoporosis.
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available in clinical practice. Other therapeutic targets
include the B cell, which is deleted by the anti-CD20
monoclonal antibody rituximab and the CD80/CD86–
CD28 co-stimulatory signal required for T-cell activation,
which is blocked by the recombinant fusion protein
abatacept. However, RA treatment is still far from satis-
factory as  20–40% of the patients do not respond to
TNF inhibitors administered either alone or in combination
with DMARDs [100].
Although there are few head-to-head comparisons for
TNF, IL-1 and -6 activity in the same biological system,
there is evidence of complex interactions between these
cytokines. Table 1 summarizes, in the authors’ opinion,
the characteristics that distinguish IL-6 activity from
other pro-inflammatory cytokines. Given these differences
and the multiple roles of IL-6 in the immune response and
inflammation, therapies that disrupt IL-6 signalling offer an
important treatment option for RA (Fig. 4). Indeed, results
from Phase III clinical trials of IL-6 inhibition with the
monoclonal antibody tocilizumab in patients with RA
are confirming this promise [101–103].
Summary
IL-6 is the most abundant cytokine in the serum and SF of
patients with RA and levels correlate with both disease
activity and joint destruction. IL-6 signalling occurs
through both membrane-bound and soluble receptors.
IL-6 is a multitarget cytokine with activity relevant to RA
TABLE 1 Summary of the characteristics that suggest a
distinctive role of IL-6 in RA (based on the authors’
extensive knowledge of the available literature)
Features IL-6 TNF IL-1
Levels in blood and SF þþþþ þ þ
Local effects
Endothelial activation þþ þþ þ
Polymorphonuclear cells
(neutrophil migration)
þþ þ þ
Proteases, MMP secretion þ þþ þþþ
Bone-derived cell activity
(osteoclast and osteoblast)
þþ þ þ
B-cell function and survival þþþ   þ
Th17 differentiation þþ   þþ
Systemic effects
Acute-phase protein production þþþ þ þ
Bone marrow (anaemia) þþ þ þ
CNS (fatigue) þþþ þþ þþ
The level of activity is represented by crosses, with an
increased number of crosses representing increased activity.
FIG.4 Potential sites for intervention in RA. Based on the present knowledge of RA pathogenesis, therapeutic strategies
can influence the outcome of initial or late-phase processes. IL-6 inhibition can influence the initial autoimmune
reaction between antigen-presenting cells and T and B cells or the later stage in tissue destruction when synovial
cells, chondrocytes and bone-derived cells are involved.
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role in the inflammatory process, in osteoclast-mediated
bone resorption and in pannus development through
increased VEGF expression. IL-6 is pro-inflammatory,
induces acute-phase proteins (including CRP) and
contributes to the systemic manifestations of RA though
hepcidin production (anaemia), its potent action on the
HPA axis (fatigue) and its impact on bone metabolism
(osteoporosis). In addition, IL-6 may contribute to the
induction and maintenance of the autoimmune process
through B-cell modulation and Th17 cell differentiation.
In combination, these findings make IL-6 activity a logical
target for inhibition in patients with RA. This observation is
supported by Phase III studies using an anti-IL-6R
antibody, which have demonstrated benefits of IL-6R
inhibition across a number of patient populations with RA.
Rheumatology key messages
. IL-6 is a pleiotropic cytokine.
. IL-6 plays a role in the local and systemic manifes-
tations of RA.
. The IL-6 receptor offers an important treatment
option for RA.
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